BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
Clinical trial NCT00931801 · COMPLETED
Trial details
- NCT number
- NCT00931801
- Sponsor
- Community Research Initiative of New England
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-01
- Primary completion
- 2012-02-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.